

HPLC QUANTIFICATION AND IMPURITY PROFILING OF COUNTERFEIT SILDENAFIL TABLETS FROM THE AFRICAN MARKET

FOUAD ECHERFAOUI, HOUDA BOUCHAFRA, CASIMIR ADADE ADADE, ABDELHAFID BENOMAR, MOUNIR EL KACIMI, AIMEN EL ORCHE, KHADIJA EL BOURAKADI, MUSTAPHA BOUATIA, MILOUD EL KARBANE

References:

1. Septifani, E. A.; Yetti, R. D.; Asra, R. The Discovery and Development of Sildenafil Citrate. *Asian J. Pharm. Res. Dev.* **2021**, *9* (4), 108–117.
2. Jackson, G.; Gillies, H.; Osterloh, I. Past, Present, and Future: A 7-Year Update of Viagra® (Sildenafil Citrate). *Int. J. Clin. Pract.* **2005**, *59* (6), 680–691.
3. Reis, N. F. A.; et al. UHPLC for Quality Evaluation of Genuine and Illegal Medicines Containing Sildenafil Citrate and Tadalafil. *J. Chromatogr. Sci.* **2021**, *59* (1), 30–39.
4. El-Dahiyat, F.; et al. Combatting Substandard and Falsified Medicines: Public Awareness and Identification of Counterfeit Medications. *Front. Public Health* **2021**, *9*, 754279.
5. Amico, K.; Aaronson, E.; Zucker, H. Innovations to Address Global Drug Counterfeiting: Implications for Urbanization and Health. In *Innovating for Healthy Urbanization*; 2015; pp 141–163.
6. Terrier, J.-E.; et al. Patient Education for Radical Prostatectomy: Development of a Program Tailored to the Needs of Prostate Cancer Patients. *Am. J. Men's Health* **2021**, *15* (6), 15579883211063317.
7. Van Baelen, M.; et al. Fighting Counterfeit Medicines in Europe: The Effect on Access to Medicines. *SAGE Publications* **2017**, London, England, maapoc.0000010.
8. Jackson, G.; et al. Counterfeit Phosphodiesterase Type 5 Inhibitors Pose Significant Safety Risks. *Int. J. Clin. Pract.* **2010**, *64* (4), 497–504.
9. Yadav, S.; Rawal, G. Counterfeit Drugs: Problem of Developing and Developed Countries. *Int. J. Pharm. Chem. Anal.* **2015**, *2* (1), 46–50.
10. White, C. M. Counterfeit Drugs: A Major Issue for Vulnerable Citizens throughout the World and in the United States. *J. Am. Pharm. Assoc.* **2021**, *61* (1), e93–e98.
11. Neto, J. C.; Lisboa, F. L. ATR-FTIR Characterization of Generic, Brand-Named, and Counterfeit Sildenafil- and Tadalafil-Based Tablets Found on the Brazilian Market. *Sci. Justice* **2017**, *57* (4), 283–295.
12. Fidan, A. K.; Bakirdere, S. Simultaneous Determination of Sildenafil and Tadalafil in Legal Drugs, Illicit/Counterfeit Drugs, and Wastewater Samples by High-Performance Liquid Chromatography. *J. AOAC Int.* **2016**, *99* (4), 923–928.
13. Daraghmeh, N.; et al. Determination of Sildenafil Citrate and Related Substances in Commercial Products and Tablet Dosage Form Using HPLC. *J. Pharm. Biomed. Anal.* **2001**, *25* (3–4), 483–492.
14. Nsairat, H.; et al. In Vitro Dissolution Equivalence of Jordanian Sildenafil Generics via Validated, Stability-Indicating HPLC Method. *Bioanalysis* **2024**.
15. Ntontis, S.; et al. Analytical Quality by Design Approach for the Determination of Imidazole in Sildenafil API and Its Formulations Using Zwitterionic HILIC Stationary Phase. *J. Pharm. Biomed. Anal.* **2023**, *224*, 115186.
16. Gadekar, G. R.; et al. A Validated Simple, Rapid and Accurate RP-HPLC Approach for Measuring Vardenafil Hydrochloride Trihydrate in Bulk Drugs and Medicinal Formulations. *Indian J. Pharm. Educ. Res.* **2024**, *58* (2s), s532–s542.
17. Benckekroun, Y. H.; et al. Application of Design Space, Uncertainty, and Risk Profile Strategies to the Development and Validation of UPLC Method for the Characterization of Four Authorized Phosphodiesterase Type 5 Inhibitors to Combat Counterfeit Drugs. *J. AOAC Int.* **2020**, *103* (3), 715–724.
18. Patel, D. N.; et al. Screening of Synthetic PDE-5 Inhibitors and Their Analogues as Adulterants: Analytical Techniques and Challenges. *J. Pharm. Biomed. Anal.* **2014**, *87*, 176–190.
19. Mabrouk, M.; et al. Analysis of Counterfeit Sildenafil by Validated UV Spectrophotometric Methods. *J. Adv. Med. Pharm. Res.* **2021**, *2* (2), 56–63.
20. Tanna, S.; Armitage, R. IR Spectroscopic Analytical Tools in the Fight Against Counterfeit Medicines. In *Quantitative and Qualitative Determination Technologies of Counterfeit Drugs*; 2023; pp 41.
21. Lanzarotta, A.; et al. Analytical Tools for Examining Counterfeit Drug Products. In *Trends in Counterfeit Drugs*; 2023; pp 151–222.
22. Kalicka, A.; Tarłowska, N. Counterfeit and Illegal Medicinal Products as an Example of Drugs That Do Not Meet the Basic Quality Requirements. *Prospects Pharm. Sci.* **2023**, *21* (4), 10–23.
23. Ala'Y, S.; et al. Optimization and Validation of HPLC-UV Method for the Determination of Vardenafil, Sildenafil, and Tadalafil in Honey-Mixed Herbal Sachets Using a Design of Experiment. *Jordan J. Pharm. Sci.* **2023**, *16* (1), 148–162.
24. Hossain, C. F.; Al-Amin, M.; Sultana, G. N. N. Use of HPLC with a Photodiode Array Detector to Identify Sildenafil Citrate as an Adulterant in Herbal Products of Bangladesh. **2023**.

25. El Menebbely, A. A Study of the Principles of the Organization of Pharmaceutical Care in Morocco and the Countries of the World. **2023**.
26. Abdel-Kader, M. S.; et al. Eco-Friendly Stability-Indicating RP-HPTLC Method for Sildenafil Analysis, Characterization and Biological Evaluation of Its Oxidized Stress Degradation Product. *Sci. Rep.* **2021**, *11* (1), 15358.
27. Veronin, M. A.; Nutan, M. T.; Dodla, U. K. R. Quantification of Active Pharmaceutical Ingredient and Impurities in Sildenafil Citrate Obtained from the Internet. *Ther. Adv. Drug Saf.* **2014**, *5* (5), 180–189.
28. Taher, A.; Setiawati, A. VICTORY Project: A Study of Counterfeit PDE5 Inhibitor (Sildenafil) in Indonesia. *Acta Med. Indones.* **2013**, *45* (4), 290–294.
29. Krüger, A.; et al. Quality Assessment of Seized Sildenafil-Labelled Tablets.
30. Stecher, V. J.; et al. Analysis of Pharmaceuticals Seized by Authorities in the United Kingdom for Suspicion of Being Counterfeit VIAGRA® (Sildenafil Citrate). *J. Men's Health* **2010**, *7* (3), 321–321.
31. Blok-Tip, L.; et al. Counterfeits and Imitations of Viagra and Cialis Tablets: Trends and Risks to Public Health—A Survey of the Analyses Carried Out at the Dutch National Institute for Public Health and the Environment in the Time Period 2000–2004; **2005**.